Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

KalVista Pharmaceuticals (KALV) Assets Average (2017 - 2025)

KalVista Pharmaceuticals' Assets Average history spans 10 years, with the latest figure at $272.8 million for Q2 2025.

  • On a quarterly basis, Assets Average rose 56.16% to $272.8 million in Q2 2025 year-over-year; TTM through Apr 2025 was $272.8 million, a 56.16% increase, with the full-year FY2025 number at $243.1 million, up 16.14% from a year prior.
  • Assets Average hit $272.8 million in Q2 2025 for KalVista Pharmaceuticals, up from $227.8 million in the prior quarter.
  • Over the last five years, Assets Average for KALV hit a ceiling of $272.8 million in Q2 2025 and a floor of $70.8 million in Q1 2021.
  • Historically, Assets Average has averaged $180.8 million across 4 years, with a median of $174.7 million in 2024.
  • The widest YoY moves for Assets Average: up 73.03% in 2021, down 34.11% in 2021.
  • Tracing KALV's Assets Average over 4 years: stood at $169.1 million in 2021, then dropped by 11.57% to $149.5 million in 2023, then soared by 52.35% to $227.8 million in 2024, then increased by 19.74% to $272.8 million in 2025.
  • Business Quant data shows Assets Average for KALV at $272.8 million in Q2 2025, $227.8 million in Q4 2024, and $180.5 million in Q4 2024.